Molecular aspects of cyclophilins mediating therapeutic actions of their ligands.
about
From Drosophila to humans: reflections on the roles of the prolyl isomerases and chaperones, cyclophilins, in cell function and diseaseHuman nucleoporins promote HIV-1 docking at the nuclear pore, nuclear import and integration.The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitorsThe TPR domain in the host Cyp40-like cyclophilin binds to the viral replication protein and inhibits the assembly of the tombusviral replicaseProteome-wide characterization of signalling interactions in the hippocampal CA4/DG subfield of patients with Alzheimer's disease.Targeting the cyclophilin domain of Ran-binding protein 2 (Ranbp2) with novel small molecules to control the proteostasis of STAT3, hnRNPA2B1 and M-opsin.Heterogeneous susceptibility of circulating SIV isolate capsids to HIV-interacting factorsCyclophilin A binds to the viral RNA and replication proteins, resulting in inhibition of tombusviral replicase assemblyDifferential loss of prolyl isomerase or chaperone activity of Ran-binding protein 2 (Ranbp2) unveils distinct physiological roles of its cyclophilin domain in proteostasis.Unraveling the role of peptidyl-prolyl isomerases in neurodegeneration.Advances in the current treatment of autoimmune hepatitis.Drug choices in autoimmune hepatitis: part B--Nonsteroids.Functional diversity and pharmacological profiles of the FKBPs and their complexes with small natural ligands.Detection of the mechanism of immunotoxicity of cyclosporine A in murine in vitro and in vivo models.Synthesis of the C21-C34 fragment of antascomicin B.Immunophilin-protein interactions in Plasmodium falciparum.A homolog of cyclophilin D is expressed in Trypanosoma cruzi and is involved in the oxidative stress-damage response.The spliceosomal proteins PPIH and PRPF4 exhibit bi-partite binding.Peptidylprolyl Isomerases as In Vivo Carriers for Drugs That Target Various Intracellular Entities.The antimalarial action of FK506 and rapamycin: evidence for a direct effect on FK506-binding protein PfFKBP35.
P2860
Q26829060-3CA65008-EA40-4C8D-A6BE-019DD58B9A14Q31103609-A1B1B7A6-7A84-4BB9-964A-5C88723CA7F6Q34064211-A9002A26-B973-4238-A501-565980711EB3Q34162254-5264D961-B733-4F27-A610-5597CE9E65F0Q35713134-9E2E8978-AC6A-49E5-9E01-2EC05EA3BCB3Q36016095-90699279-C4D1-41B2-BA94-12EE0A254590Q37116045-3CF3CF36-714E-442F-9CE8-C3A0F6200289Q37336768-D86A0768-5A8E-4E61-BEE1-3066DAA09356Q37596297-FC3E89B4-3664-4E73-B759-A0C72BF6B47DQ37873359-9DC5E699-89EE-4245-A271-81CF2C01B743Q38000056-E0A032F0-E0CB-4F3D-B07E-E8A550C99E42Q38051706-37D2A062-A102-4C33-895B-5FF212DEFF55Q38065993-81620105-118B-4827-B673-09DC00D5D187Q38956307-85AFDCA9-0833-424C-94FA-C5E985A5C27BQ39954180-88E22046-306E-47A4-ADC1-98C5ACED2CA7Q41117416-28358AE1-BF81-48B4-9EB0-EA8D46580A85Q41835653-813115DA-398A-4177-B722-7340404C7F9CQ43208870-24224B6A-85FC-4C76-9561-0FB009627A23Q47134039-B4AB4D11-0D3D-4573-83E2-AB5F799972B3Q47988678-D0B00B03-C890-4182-AA1E-4EDF1BC19643
P2860
Molecular aspects of cyclophilins mediating therapeutic actions of their ligands.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 July 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Molecular aspects of cyclophilins mediating therapeutic actions of their ligands.
@en
Molecular aspects of cyclophilins mediating therapeutic actions of their ligands.
@nl
type
label
Molecular aspects of cyclophilins mediating therapeutic actions of their ligands.
@en
Molecular aspects of cyclophilins mediating therapeutic actions of their ligands.
@nl
prefLabel
Molecular aspects of cyclophilins mediating therapeutic actions of their ligands.
@en
Molecular aspects of cyclophilins mediating therapeutic actions of their ligands.
@nl
P2860
P1476
Molecular aspects of cyclophilins mediating therapeutic actions of their ligands.
@en
P2093
Andrzej Galat
Jacqueline Bua
P2860
P2888
P304
P356
10.1007/S00018-010-0437-0
P577
2010-07-04T00:00:00Z